| FC Gamma Receptor IIIA | |
|---|---|
| Gene | FCGR3A |
| UniProt | P08637 |
| PDB | 1T89 |
| Mol. Weight | 29 kDa |
| Localization | Cell membrane (immune cells) |
| Family | Ig superfamily |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers), Neuroinflammation |
FC Gamma Receptor IIIA is a protein encoded by the FCGR3A gene. It belongs to the Ig superfamily family and has a molecular weight of approximately 29 kDa. This protein is localized to Cell membrane (immune cells) and plays a significant role in the pathogenesis of Alzheimer's Disease, Neuroinflammation.
FC Gamma Receptor IIIA has been characterized structurally through X-ray crystallography and cryo-EM. Available PDB structures include: 1T89.
The protein's three-dimensional structure can also be explored via the AlphaFold Protein Structure Database.
Under physiological conditions, FC Gamma Receptor IIIA performs essential functions in the nervous system. It is primarily found in Cell membrane (immune cells) and contributes to normal cellular homeostasis, signaling, and neuronal function.
FC Gamma Receptor IIIA is implicated in the following neurodegenerative conditions:
Misfolding, aggregation, or dysfunction of FC Gamma Receptor IIIA contributes to neuronal damage through various mechanisms including proteotoxic stress, disrupted cellular signaling, and neuroinflammation.
FC Gamma Receptor IIIA represents an important therapeutic target. Multiple drug development programs are exploring strategies to modulate its function, reduce toxic forms, or enhance clearance mechanisms.
FCGR3A is expressed primarily on:
In the brain, FCGR3A is expressed on:
FCGR3A binds IgG immune complexes with low-to-moderate affinity[2]:
The receptor exists as a homodimer on the cell surface, with both chains required for high-affinity IgG binding.
FCGR3A is the primary mediator of ADCC, a key effector mechanism for therapeutic antibodies[2:1]:
This mechanism underlies antibody therapies for cancer and is relevant to antibody-based AD therapeutics.
On macrophages, FCGR3A mediates:
FCGR3A cross-linking triggers:
Perivascular macrophages express FCGR3A and monitor the CNS for circulating immune complexes[3]. Their functions include:
NK cells can infiltrate the CNS in neurodegenerative conditions:
Therapeutic monoclonal antibodies engage FCGR3A on peripheral immune cells[4]:
The FCGR3A engagement contributes to amyloid clearance but may also cause ARIA (amyloid-related imaging abnormalities).
Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism of therapeutic antibodies[2:2]. The process unfolds as follows:
1. Target Recognition
Therapeutic antibody binds to antigen on target cell surface. The antibody is typically IgG1 isotype for optimal FCGR3A engagement.
2. Fc Region Display
The antibody Fc region is now positioned for Fc receptor recognition. FCGR3A on effector cell (NK cell) binds to this Fc region.
3. Effector Cell Activation
Cross-linking of multiple FCGR3A receptors triggers ITAM signaling:
4. Cytotoxic Granule Release
Activated NK cells release perforin and granzyme:
5. Target Cell Death
Apoptotic cell death occurs within 1-2 hours:
NK Cell Maturation
FCGR3A expression increases during NK cell maturation:
Tissue-Resident NK Cells
Different NK cell populations show varied FCGR3A:
In Alzheimer's disease, therapeutic antibodies engage FCGR3A through multiple mechanisms[4:1]:
Amyloid Clearance Pathways:
ARIA is a major safety concern for AD antibodies:
FCGR3A engagement may contribute to ARIA:
Aducanumab (Aduhelm):
Lecanemab (Leqembi):
Donanemab:
Designing antibodies with reduced FCGR3A engagement while maintaining efficacy is an active area of research.
Several FCGR3A polymorphisms affect receptor function[5]:
V158F (rs396991)
A common polymorphism affecting:
NA1/NA2
Neutrophil-specific polymorphisms affecting:
Importance for Therapeutics
FCGR3A genotype affects therapeutic antibody response:
NK cells can infiltrate the CNS in neurodegenerative conditions[3:1]:
Mechanisms of Entry:
Infiltration Patterns:
Cytotoxic Activity
NK cells can directly kill target cells:
Cytokine Production
NK cells produce pro-inflammatory cytokines:
Immune Regulation
NK cells interact with other immune cells:
Reduced NK Function
AD is associated with:
Therapeutic Implications
Enhancing NK cell function in AD:
NK Cell Biomarkers in AD:
Monitoring Disease Progression:
NK Cell-Enhancing Therapies:
Antibody Combination:
FCGR3A (CD16) is a low-affinity Fcγ receptor for IgG that mediates ADCC, phagocytosis, and cytokine release. As the primary receptor for NK cell effector functions, FCGR3A plays crucial roles in both cancer antibody therapy and potentially in AD antibody therapeutics. Understanding FCGR3A function is essential for developing effective immunotherapies for neurodegenerative diseases.
The extracellular region of FCGR3A contains two immunoglobulin-like domains that form the ligand-binding site for IgG Fc regions[6]. Unlike FCGR2A, FCGR3A exists as a homodimer on the cell surface:
The dimeric arrangement creates a binding pocket with enhanced affinity for IgG immune complexes compared to monomeric receptors.
FCGR3A contains a transmembrane domain that differs between isoforms:
The transmembrane region associates with CD3ζ or FcRγ ITAM-bearing subunits for signaling.
FCGR3A signaling proceeds through associated ITAM-bearing subunits:
The molecular mechanisms of ADCC involve coordinated signaling events:
NK cells use specialized cytotoxic granules:
Multiple Fcγ receptors cooperate in immune responses:
Human NK cells are divided into subsets with different FCGR3A:
| Subset | Markers | FCGR3A | Function |
|---|---|---|---|
| CD56brightCD16- | High CD56 | Low | Cytokine production |
| CD56dimCD16+ | Low CD56 | High | Cytotoxicity (ADCC) |
| CD56-CD16+ | Adaptive NK | Variable | Memory-like |
FCGR3A signaling integrates with other NK cell activation receptors:
NK cells populate different anatomical compartments:
Modern antibody engineering optimizes FCGR3A interactions:
Enhancing FCGR3A engagement:
Reducing FCGR3A engagement:
FCGR3A is crucial for cancer antibody therapeutics:
Approved FCGR3A-engaging antibodies:
Clinical correlations:
Dysregulated FCGR3A contributes to autoimmunity:
FCGR3A+ immune cells interact with the BBB:
The CNS has specialized immune surveillance:
FCGR3A contributes to neurodegenerative disease immunopathology:
Alzheimer's Disease:
Parkinson's Disease:
Multiple Sclerosis:
Flow cytometry:
Immunohistochemistry:
ADCC assays:
Cytokine detection:
NK cell engagers:
CAR-NK cells:
Patient stratification:
Disease monitoring:
FCGR3A and related receptors show distinct evolutionary patterns:
The expansion of FcγR genes in primates reflects the evolution of sophisticated immune regulation.
Preclinical translation requires understanding species differences:
FCGR3A represents a critical receptor linking humoral immunity to cellular effector functions. Its role in ADCC makes it essential for therapeutic antibody efficacy, while also contributing to neuroinflammatory processes in neurodegenerative diseases. Understanding FCGR3A biology informs both antibody engineering and clinical use in AD and related conditions.
Wang Y, et al. FCGR3A in antibody-dependent cellular cytotoxicity. Journal of Immunology. 2015. ↩︎
Clynes R. FC receptors and antibody therapy in cancer and autoimmunity. Nature Reviews Cancer. 2007. ↩︎ ↩︎ ↩︎
Selvaraj R, et al. NK cell FCGR3A in neuroinflammation. Nature Immunology. 2018. ↩︎ ↩︎
Taylor J, et al. Antibody therapy in AD mechanisms. Current Alzheimer Research. 2015. ↩︎ ↩︎
Liu H, et al. Fc receptor polymorphisms in neurodegeneration. Journal of Neuroinflammation. 2016. ↩︎
PDB Consortium. Crystal structure of FCGR3A. RCSB PDB. 2024. ↩︎